Patrys Limited (ASX:PAB)
0.0350
-0.0030 (-7.89%)
Mar 4, 2026, 3:22 PM AEST
Patrys Revenue
Patrys had revenue of 98.08K AUD in the half year ending June 30, 2025, a decrease of -90.44%. This brings the company's revenue in the last twelve months to 100.38K, down -93.10% year-over-year. In the fiscal year ending June 30, 2025, Patrys had annual revenue of 828.54K, down -40.57%.
Revenue (ttm)
100.38K
Revenue Growth
-93.10%
P/S Ratio
202.67
Revenue / Employee
10.04K
Employees
10
Market Cap
20.34M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 828.54K | -565.62K | -40.57% |
| Jun 30, 2024 | 1.39M | -1.46M | -51.11% |
| Jun 30, 2023 | 2.85M | -481.67K | -14.45% |
| Jun 30, 2022 | 3.33M | 2.00M | 149.08% |
| Jun 30, 2021 | 1.34M | 565.53K | 73.18% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Immuron | 7.48M |
| Neurotech International | 7.07M |
| Tissue Repair | 3.26M |
| Noxopharm | 2.68M |
| Avecho Biotechnology | 1.24M |
| Argenica Therapeutics | 1.01M |
| AdAlta | 608.07K |
| Bio-Gene Technology | 390.63K |